Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'OXIDATION POLYMORPHISM' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 171 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Leis, HJ; Windischhofer, W; Raspotnig, G; Fauler, G
      Stable isotope dilution negative ion chemical ionization gas chromatography-mass spectrometry for the quantitative analysis of paroxetine in human plasma

      JOURNAL OF MASS SPECTROMETRY
    2. Zanger, UM; Fischer, J; Raimundo, S; Stuven, T; Evert, BO; Schwab, M; Eichelbaum, M
      Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6

      PHARMACOGENETICS
    3. Brosen, K; Naranjo, CA
      Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    4. Goldstein, JA
      Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    5. Hemeryck, A; De Vriendt, CA; Belpaire, FM
      Metoprolol-paroxetine interaction in human liver microsomes: Stereoselective aspects and prediction of the in vivo interaction

      DRUG METABOLISM AND DISPOSITION
    6. Laine, K; Tybring, G; Hartter, S; Andersson, K; Svensson, JO; Widen, J; Bertilsson, L
      Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    7. Kirchheiner, J; Brosen, K; Dahl, ML; Gram, LF; Kasper, S; Roots, I; Sjoqvist, F; Spina, E; Brockmoller, J
      CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

      ACTA PSYCHIATRICA SCANDINAVICA
    8. Basile, VS; Ozdemir, V; Masellis, M; Walker, ML; Heltzer, HY; Lieberman, JA; Potkin, SG; Alva, G; Kalow, W; Macciardi, FM; Kennedy, JL
      A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

      MOLECULAR PSYCHIATRY
    9. Jurima-Romet, M; Casley, WL; Leblanc, CA; Nowakowska, M
      Evidence for the catalysis of dextromethorphan O-demethylation by a CYP2D6-like enzyme in pig liver

      TOXICOLOGY IN VITRO
    10. Wang, XY; Levy, RH; Ho, RJY
      Development of a semi-quantitative assay to detect full-length CYP2C19 RNA

      BIOTECHNIQUES
    11. Dalen, P; Dahl, ML; Andersson, K; Bertilsson, L
      Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    12. Poolsup, N; Po, ALW; Knight, TL
      Pharmacogenetics and psychopharmacotherapy

      JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
    13. Albers, LJ; Reist, C; Vu, RL; Fujimoto, K; Ozdemir, V; Helmeste, D; Poland, R; Tang, SW
      Effect of venlafaxine on imipramine metabolism

      PSYCHIATRY RESEARCH
    14. Hiemke, C; Hartter, S
      Pharmacokinetics of selective serotonin reuptake inhibitors

      PHARMACOLOGY & THERAPEUTICS
    15. Rasmussen, BB; Brosen, K
      Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?

      THERAPEUTIC DRUG MONITORING
    16. Tucker, GT
      Advances in understanding drug metabolism and its contribution to variability in patient response

      THERAPEUTIC DRUG MONITORING
    17. Miksys, S; Rao, Y; Sellers, EM; Kwan, M; Mendis, D; Tyndale, RF
      Regional and cellular distribution of CYP2D subfamily members in rat brain

      XENOBIOTICA
    18. O'Neil, WM; Gilfix, BM; Markoglou, N; Di Girolamo, A; Tsoukas, CM; Wainer, IW
      Genotype and phenotype of cytochrome P-450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    19. Haffen, E; Vandel, P; Paintaud, G; Broly, F; Vandel, S; Bonin, B; Bizouard, P; Sechter, D; Bechtel, PR
      Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    20. Herrlin, K; Massele, AY; Rimoy, G; Alm, C; Rais, M; Ericsson, O; Bertilsson, L; Gustafsson, LL
      Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    21. Damkier, P; Brosen, K
      Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    22. Yoon, YR; Cha, IJ; Shon, JH; Lim, KA; Cha, YN; Jang, IJ; Park, CW; Shin, SG; Flockhart, DA; Shin, JG
      Relationship of paroxetine disposition to metoprolol metabolic ratio and CPsi P2D6*10 genotype of Korean subjects

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    23. Hemeryck, A; Lefebvre, RA; De Vriendt, C; Belpaire, FM
      Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    24. Wormhoudt, LW; Commandeur, JNM; Vermeulen, NPE
      Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-Transferase, and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity

      CRITICAL REVIEWS IN TOXICOLOGY
    25. Rostami-Hodjegan, A; Kroemer, HK; Tucker, GT
      In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity

      PHARMACOGENETICS
    26. Kaneko, A; Bergqvist, Y; Taleo, G; Kobayakawa, T; Ishizaki, T; Bjorkman, A
      Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations

      PHARMACOGENETICS
    27. Daniel, WA; Syrek, M; Wojcikowski, J
      The influence of selective serotonin reuptake inhibitors on the plasma andbrain pharmacokinetics of the simplest phenothiazine neuroleptic promazinein the rat

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    28. Masubuchi, Y; Konishi, M; Horie, T
      Imipramine- and mianserin-induced acute cell injury in primary cultured rat hepatocytes: implication of different cytochrome P450 enzymes

      ARCHIVES OF TOXICOLOGY
    29. Bramer, SL; Suri, A
      Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol

      CLINICAL PHARMACOKINETICS
    30. DeVane, CL
      Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors

      CELLULAR AND MOLECULAR NEUROBIOLOGY
    31. Greenblatt, DJ; Von Moltke, LL; Harmatz, JS; Shader, RI
      Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    32. Avenoso, A; Facciola, G; Scordo, MG; Spina, E
      No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers

      THERAPEUTIC DRUG MONITORING
    33. Ohman, R; Hagg, S; Carleborg, L; Spigset, O
      Excretion of paroxetine into breast milk

      JOURNAL OF CLINICAL PSYCHIATRY
    34. Ibeanu, GC; Blaisdell, J; Ferguson, RJ; Ghanayem, BI; Brosen, K; Benhamou, S; Bouchardy, C; Wilkinson, GR; Dayer, P; Goldstein, JA
      A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    35. Glue, P; Andersen, KO; Hansen, MA; Stage, KB; Hansen, H; Norrie, B; Hansen, PEB; Knudsen, L; Thomsen, R; Pedersen, I; Jessen, IM; Haffner, F; Hansen, JB; Berthou, E; Kierkegaard, H; Andersen, TH; Bjarking, L; Bech, P; Bendsen, BB; Spanager, S; LaBianca, J; Jha, S; Hoybye, E; Bysted, M; Rasmussen, NA; Moller, AG; Welter, H; Justesen, EM; Merinder, L; Andersen, F; Bartels, U; Borg, L; Christensen, J; Weeke, A; Raben, H; Larsen, JK; Knudsen, H; Jorgensen, O; Knudsen, AF; Horsboll, H; Waago, K; Christensen, B; Christensen, NB; Thiesen, S; Wernlund, HH; Thomsen, IS; Christensen, EM; Skovgaard, K; Andersen, J; Andersen, M; Gram, LF; Brosen, K; Sindrup, SH; Fugmann, S; de Lasson, AR; Andersen, D; Gram, LF; Kragh-Sorensen, P; Bech, P; Bolwig, TG; Vestergaard, P; Larsen, JK
      Clomipramine dose-effect study in patients with depression: Clinical end points and pharmacokinetics

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    36. SHIN JG; KIM KA; YOON YR; CHA IJ; KIM YH; SHIN SG
      RAPID SIMPLE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OFPAROXETINE IN HUMAN PLASMA

      Journal of chromatography B. Biomedical sciences and applications
    37. Ryu, SW; Kim, YJ; Kim, E
      Mutation analysis of CYP2D6 locus in the Korean population: Identificationof rare poor metabolizer alleles at the nucleotide level

      MOLECULES AND CELLS
    38. IBEANU GC; BLAISDELL J; GHANAYEM BI; BEYELER C; BENHAMOU S; BOUCHARDY C; WILKINSON GR; DAYER P; DALY AK; GOLDSTEIN JA
      AN ADDITIONAL DEFECTIVE ALLELE, CYP2C19-ASTERISK-5, CONTRIBUTES TO THE S-MEPHENYTOIN POOR METABOLIZER PHENOTYPE IN CAUCASIANS

      Pharmacogenetics
    39. GRIESE EU; ZANGER UM; BRUDERMANNS U; GAEDIGK A; MIKUS G; MORIKE K; STUVEN T; EICHELBAUM M
      ASSESSMENT OF THE PREDICTIVE POWER OF GENOTYPES FOR THE IN-VIVO CATALYTIC FUNCTION OF CYP2D6 IN A GERMAN POPULATION

      Pharmacogenetics
    40. NEMES KB; HORVATH V; GREZAL G; HORVAI G; HRABECZYPALL A; KOCSI E; DRABANT S; CSORGO M; RENCZES G; KLEBOVICH I
      FOOD INTERACTION PHARMACOKINETIC STUDY OF CORDAFLEX-20MG RETARD FILM TABLET IN HEALTHY-VOLUNTEERS

      International journal of clinical pharmacology and therapeutics
    41. ODONOHOE A; GILL M
      PHARMACOGENETICS OF THE HEPATIC CYTOCHROME-P450 ENZYME-SYSTEM - ITS RELEVANCE FOR PRESCRIBING IN PSYCHIATRY

      Irish journal of psychological medicine
    42. HOSKINS JM; SHENFIELD GM; GROSS AS
      RELATIONSHIP BETWEEN PROGUANIL METABOLIC RATIO AND CYP2C19 GENOTYPE IN A CAUCASIAN POPULATION

      British journal of clinical pharmacology
    43. OZDEMIR V; NARANJO CA; SHULMAN RW; HERRMANN N; SELLERS EM; REED K; KALOW W
      DETERMINANTS OF INTERINDIVIDUAL VARIABILITY AND EXTENT OF CYP2D6 AND CYP1A2 INHIBITION BY PAROXETINE AND FLUVOXAMINE IN-VIVO

      Journal of clinical psychopharmacology
    44. BAUMANN P
      CARE OF DEPRESSION IN THE ELDERLY - COMPARATIVE PHARMACOKINETICS OF SSRIS

      International clinical psychopharmacology
    45. EAP CB; LIMA CAD; MACCIARDI F; WOGGON B; POWELL K; BAUMANN P
      STEADY-STATE CONCENTRATIONS OF THE ENANTIOMERS OF MIANSERIN AND DESMETHYLMIANSERIN IN POOR AND IN HOMOZYGOUS AND HETEROZYGOUS EXTENSIVE METABOLIZERS OF DEBRISOQUINE

      Therapeutic drug monitoring
    46. BAKER GB; FANG J; SINHA S; COUTTS RT
      METABOLIC-DRUG INTERACTIONS WITH SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRI) ANTIDEPRESSANTS

      Neuroscience and biobehavioral reviews
    47. Smith, DA; Abel, SM; Hyland, R; Jones, BC
      Human cytochrome P450s: selectivity and measurement in vivo

      XENOBIOTICA
    48. POULSEN L; RIISHEDE L; BROSEN K; CLEMENSEN S; SINDRUP SH
      CODEINE IN POSTOPERATIVE PAIN - STUDY OF THE INFLUENCE OF SPARTEINE PHENOTYPE AND SERUM CONCENTRATIONS OF MORPHINE AND MORPHINE-6-GLUCURONIDE

      European Journal of Clinical Pharmacology
    49. KOYTCHEV R; ALKEN RG; VLAHOV V; KIRKOV V; KANEVA R; THYROFFFRIESINGER U; REHAK E
      INFLUENCE OF THE CYTOCHROME P4502D6-ASTERISK-4 ALLELE ON THE PHARMACOKINETICS OF CONTROLLED-RELEASE METOPROLOL

      European Journal of Clinical Pharmacology
    50. Rasmussen, BB; Nielsen, TL; Brosen, K
      Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    51. IBEANU GC; GOLDSTEIN JA; MEYER U; BENHAMOU S; BOUCHARDY C; DAYER P; GHANAYEM BI; BLAISDELL J
      IDENTIFICATION OF NEW HUMAN CYP2C19 ALLELES (CYP2C19-ASTERISK-6 AND CYP2C19-ASTERISK-2B) IN A CAUCASIAN POOR METABOLIZER OF MEPHENYTOIN

      The Journal of pharmacology and experimental therapeutics
    52. FERGUSON RJ; DEMORAIS SMF; BENHAMOU S; BOUCHARDY C; BLAISDELL J; IBEANU G; WILKINSON GR; SARICH TC; WRIGHT JM; DAYER P; GOLDSTEIN JA
      A NEW GENETIC-DEFECT IN HUMAN CYP2C19 - MUTATION OF THE INITIATION CODON IS RESPONSIBLE FOR POOR METABOLISM OF S-MEPHENYTOIN

      The Journal of pharmacology and experimental therapeutics
    53. Mamiya, K; Ieiri, I; Shimamoto, J; Yukawa, E; Imai, J; Ninomiya, H; Yamada, H; Otsubo, K; Higuchi, S; Tashiro, N
      The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics

      EPILEPSIA
    54. NOWAK MP; SELLERS EM; TYNDALE RF
      CANADIAN NATIVE INDIANS EXHIBIT UNIQUE CYP2A6 AND CYP2C19 MUTANT ALLELE FREQUENCIES

      Clinical pharmacology and therapeutics
    55. HERRLIN K; MASSELE AY; JANDE M; ALM C; TYBRING G; ABDI YA; WENNERHOLM A; JOHANSSON I; DAHL ML; BERTILSSON L; GUSTAFSSON LL
      BANTU TANZANIANS HAVE A DECREASED CAPACITY TO METABOLIZE OMEPRAZOLE AND MEPHENYTOIN IN RELATION TO THEIR CYP2C19 GENOTYPE

      Clinical pharmacology and therapeutics
    56. FOSTER RH; GOA KL
      PAROXETINE - A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC POTENTIAL IN THE MANAGEMENT OF PANIC DISORDER

      CNS DRUGS
    57. RUDORFER MV; POTTER WZ
      THE ROLE OF METABOLITES OF ANTIDEPRESSANTS IN THE TREATMENT OF DEPRESSION

      CNS DRUGS
    58. WAN J; XIE YH; XIA H; LU YQ
      AGE MIGHT INFLUENCE THE FREQUENCY-DISTRIBUTION OF METOPROLOL HYDROXYLATION POLYMORPHISM IN A CHINESE POPULATION

      Pharmacology & toxicology
    59. SKEITH KJ; HUSSAIN MS; COUTTS RT; RAMOSREMUS C; AVINAZUBIETA JA; RUSSELL AS
      ADVERSE DRUG-REACTIONS AND DEBRISOQUINE SPARTEINE (P450IID6) POLYMORPHISM IN PATIENTS WITH FIBROMYALGIA/

      Clinical rheumatology
    60. COUDORE F; BESSON A; SHRIVASTAVA R; CHEVALIER A; ESCHALIER A; LAVARENNE J; MASSINGHAM R; FIALIP J
      COMPARISON OF AMITRIPTYLINE METABOLISM IN HEPATOCYTES FROM STREPTOZOCIN-INDUCED DIABETIC RATS AND FROM NONDIABETIC RATS

      Cell biology and toxicology
    61. WANG JS; WANG W; XIE HG; HUANG SL; ZHOU HH
      EFFECT OF TROLEANDOMYCIN ON THE PHARMACOKINETICS OF IMIPRAMINE IN CHINESE - THE ROLE OF CYP3A

      British journal of clinical pharmacology
    62. BALL SE; AHERN D; SCATINA J; KAO J
      VENLAFAXINE - IN-VITRO INHIBITION OF CYP2D6 DEPENDENT IMIPRAMINE AND DESIPRAMINE METABOLISM - COMPARATIVE-STUDIES WITH SELECTED SSRIS, AND EFFECTS ON HUMAN HEPATIC CYP3A4, CYP2C9 AND CYPIA2

      British journal of clinical pharmacology
    63. ALDERMAN J; PRESKORN SH; GREENBLATT DJ; HARRISON W; PENENBERG D; ALLISON J; CHUNG M
      DESIPRAMINE PHARMACOKINETICS WHEN COADMINISTERED WITH PAROXETINE OR SERTRALINE IN EXTENSIVE METABOLIZERS

      Journal of clinical psychopharmacology
    64. GUTHRIE SK; HARIHARAN M; KUMAR AA; TANDON R
      THE EFFECT OF PAROXETINE ON THIOTHIXENE PHARMACOKINETICS

      Journal of clinical pharmacy and therapeutics
    65. THUMMEL KE; KUNZE KL; SHEN DD
      ENZYME-CATALYZED PROCESSES OF FIRST-PASS HEPATIC AND INTESTINAL DRUG EXTRACTION

      Advanced drug delivery reviews
    66. ERESHEFSKY L; ALFARO CL; LAM YWF
      TREATING DEPRESSION - POTENTIAL-DRUG INTERACTIONS

      Psychiatric annals
    67. OLESEN OV; LINNET K
      METABOLISM OF THE TRICYCLIC ANTIDEPRESSANT AMITRIPTYLINE BY CDNA-EXPRESSED HUMAN CYTOCHROME-P450 ENZYMES

      Pharmacology
    68. KORTUNAY S; BASCI NE; BOZKURT A; ISIMER A; SAYAL A; KAYAALP SO
      THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN AND PROGUANIL METABOLISM

      European Journal of Clinical Pharmacology
    69. YUE QY; SAWE J
      DIFFERENT EFFECTS OF INHIBITORS ON THE O-DEMETHYLATION AND N-DEMETHYLATION OF CODEINE IN HUMAN LIVER-MICROSOMES

      European Journal of Clinical Pharmacology
    70. SESIN J; TAMARGO J
      CLINICAL PHARMACOKINETICS OF THE CALCIUM- ANTAGONISTS

      Medicina
    71. SWANSON JR; JONES GR; KRASSELT W; DENMARK LN; RATTI F
      DEATH OF 2 SUBJECTS DUE TO IMIPRAMINE AND DESIPRAMINE METABOLITE ACCUMULATION DURING CHRONIC THERAPY - A REVIEW OF THE LITERATURE AND POSSIBLE MECHANISMS

      Journal of forensic sciences
    72. JEPPESEN U; RASMUSSEN BB; BROSEN K
      FLUVOXAMINE INHIBITS THE CYP2C19-CATALYZED BIOACTIVATION OF CHLOROGUANIDE

      Clinical pharmacology and therapeutics
    73. OZDEMIR V; NARANJO CA; HERRMANN N; REED K; SELLERS EM; KALOW W
      PAROXETINE POTENTIATES THE CENTRAL-NERVOUS-SYSTEM SIDE-EFFECTS OF PERPHENAZINE - CONTRIBUTION OF CYTOCHROME P4502D6 INHIBITION IN-VIVO

      Clinical pharmacology and therapeutics
    74. MADSEN H; RASMUSSEN BB; BROSEN K
      IMIPRAMINE DEMETHYLATION IN-VIVO - IMPACT OF CYP1A2, CYP2C19, AND CYP3A4

      Clinical pharmacology and therapeutics
    75. SHEN WW
      THE METABOLISM OF PSYCHOACTIVE-DRUGS - A REVIEW OF ENZYMATIC BIOTRANSFORMATION AND INHIBITION

      Biological psychiatry
    76. BERTILSSON L; DAHL ML; TYBRING G
      PHARMACOGENETICS OF ANTIDEPRESSANTS - CLINICAL ASPECTS

      Acta psychiatrica Scandinavica
    77. HORSMANS Y
      MAJOR CYTOCHROME-P-450 FAMILIES - IMPLICATIONS IN HEALTH AND LIVER-DISEASES

      Acta Gastro-Enterologica Belgica
    78. MARZO A; BALANT LP
      INVESTIGATION OF XENOBIOTIC METABOLISM BY CYP2D6 AND CYP2C19 - IMPORTANCE OF ENANTIOSELECTIVE ANALYTICAL METHODS

      Journal of chromatography B. Biomedical applications
    79. COHEN LJ; DEVANE CL
      CLINICAL IMPLICATIONS OF ANTIDEPRESSANT PHARMACOKINETIC AND PHARMACOGENETICS

      The Annals of pharmacotherapy
    80. PERSSON I; AKLILLU E; RODRIGUES F; BERTILSSON L; INGELMANSUNDBERG M
      S-MEPHENYTOIN HYDROXYLATION PHENOTYPE AND CYP2C19 GENOTYPE AMONG ETHIOPIANS

      Pharmacogenetics
    81. DALEN P; ALVAN G; WAKELKAMP M; OLSEN H
      FORMATION OF MEPROBAMATE FROM CARISOPRODOL IS CATALYZED BY CYP2C19

      Pharmacogenetics
    82. JURIMAROMET M; GOLDSTEIN JA; LEBELLE M; AUBIN RA; FOSTER BC; WALOP W; RODE A
      CYP2C19 GENOTYPING AND ASSOCIATED MEPHENYTOIN HYDROXYLATION POLYMORPHISM IN A CANADIAN INUIT POPULATION

      Pharmacogenetics
    83. HORSMANS Y; KANYINDA JM; DESAGER JP
      RELATIONSHIP BETWEEN MEPHENYTOIN, PHENYTOIN AND TOLBUTAMIDE HYDROXYLATIONS IN HEALTHY AFRICAN SUBJECTS

      Pharmacology & toxicology
    84. BOZKURT A; BASCI NE; ISIMER A; SAYAL A; KAYAALP SO
      METABOLIC RATIOS OF 4 PROBES OF CYP2D6 IN TURKISH SUBJECTS - A CROSS-OVER STUDY

      European journal of drug metabolism and pharmacokinetics
    85. LLERENA A; COBALEDA J; MARTINEZ C; BENITEZ J
      INTERETHNIC DIFFERENCES IN DRUG-METABOLISM - INFLUENCE OF GENETIC ANDENVIRONMENTAL-FACTORS ON DEBRISOQUINE HYDROXYLATION PHENOTYPE

      European journal of drug metabolism and pharmacokinetics
    86. BAUMANN P
      PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP OF THE SELECTIVE SEROTONIN REUPTAKE INHIBITORS

      Clinical pharmacokinetics
    87. HADASOVA E; FRANKE G; ZSCHIESCHE M; CESKOVA E; ZELENKOVA O; SIEGMUND W
      DEBRISOQUINE 4-HYDROXYLATION AND SULFAMETHAZINE N-ACETYLATION IN PATIENTS WITH SCHIZOPHRENIA AND MAJOR DEPRESSION

      British journal of clinical pharmacology
    88. SOMOGYI AA; REINHARD HA; BOCHNER F
      PHARMACOKINETIC EVALUATION OF PROGUANIL - A PROBE PHENOTYPING DRUG FOR THE MEPHENYTOIN HYDROXYLASE POLYMORPHISM

      British journal of clinical pharmacology
    89. HARVEY AT; PRESKORN SH
      CYTOCHROME-P450 ENZYMES - INTERPRETATION OF THEIR INTERACTIONS WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS .2.

      Journal of clinical psychopharmacology
    90. LANE RM
      PHARMACOKINETIC DRUG-INTERACTION POTENTIAL OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS

      International clinical psychopharmacology
    91. CONUS P; BONDOLFI C; EAP CB; MACCIARDI F; BAUMANN P
      PHARMACOKINETIC FLUVOXAMINE - CLOMIPRAMINE INTERACTION WITH FAVORABLETHERAPEUTIC CONSEQUENCES IN THERAPY-RESISTANT DEPRESSIVE PATIENT

      Pharmacopsychiatry
    92. ALBERS LJ; REIST C; HELMESTE D; VU R; TANG SW
      PAROXETINE SHIFTS IMIPRAMINE METABOLISM

      Psychiatry research
    93. BROSEN K
      DRUG-METABOLIZING-ENZYMES AND THERAPEUTIC DRUG-MONITORING IN PSYCHIATRY

      Therapeutic drug monitoring
    94. ERESHEFSKY L; RIESENMAN C; LAM YWF
      SEROTONIN SELECTIVE REUPTAKE INHIBITOR DRUG-INTERACTIONS AND THE CYTOCHROME-P450 SYSTEM

      The Journal of clinical psychiatry
    95. VIALA A; AYMARD N; LEYRIS A; CAROLI F
      PHARMACOCLINICAL CORRELATIONS IN DEPRESSE D SCHIZOPHRENIC-PATIENTS CREATED BY HALOPERIDOL DECANOATE AND FLUOXETINE

      Therapie
    96. EDSTEIN MD; YEO AET; KYLE DE; LOOAREESUWAN S; WILAIRATANA P; RIECKMANN KH
      PROGUANIL POLYMORPHISM DOES NOT AFFECT THE ANTIMALARIAL ACTIVITY OF PROGUANIL COMBINED WITH ATOVAQUONE IN-VITRO

      Transactions of the Royal Society of Tropical Medicine and Hygiene
    97. MASIMIREMBWA C; HASLER J; BERTILSSONS L; JOHANSSON I; EKBERG O; INGELMANSUNDBERG M
      PHENOTYPE AND GENOTYPE ANALYSIS OF DEBRISOQUINE HYDROXYLASE (CYP2D6) IN A BLACK ZIMBABWEAN POPULATION - REDUCED ENZYME-ACTIVITY AND EVALUATION OF METABOLIC CORRELATION OF CYP2D6

      European Journal of Clinical Pharmacology
    98. MASUBUCHI Y; IGARASHI S; SUZUKI T; HORIE T; NARIMATSU S
      IMIPRAMINE-INDUCED INACTIVATION OF A CYTOCHROME-P450 2D ENZYME IN RAT-LIVER MICROSOMES - IN RELATION TO COVALENT BINDING OF ITS REACTIVE INTERMEDIATE

      The Journal of pharmacology and experimental therapeutics
    99. KOYAMA E; CHIBA K; TANI M; ISHIZAKI T
      IDENTIFICATION OF HUMAN CYTOCHROME-P450 ISOFORMS INVOLVED IN THE STEREOSELECTIVE METABOLISM OF MIANSERIN ENANTIOMERS

      The Journal of pharmacology and experimental therapeutics
    100. NIELSEN KK; FLINOIS JP; BEAUNE P; BROSEN K
      THE BIOTRANSFORMATION OF CLOMIPRAMINE IN-VITRO, IDENTIFICATION OF THECYTOCHROME P450S RESPONSIBLE FOR THE SEPARATE METABOLIC PATHWAYS

      The Journal of pharmacology and experimental therapeutics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/02/20 alle ore 09:24:21